MARKETSSTORY 586· JULY 11, 2026

A tiny semaglutide implant is Vivani Medical's bet on the weight-maintenance problem

The hardest part of obesity treatment is keeping the weight off, and a small implant may be how one company tries to change that. The drug it would deliver is semaglutide, a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a…

NDNewsDialy Desk1 MIN READ

SOURCE

cnbc.com

← PREVIOUS STORY 585Ethereum rises 3% on tokenization interest, but derivatives weakness puts $1,800 breakout in doubt NEXT STORY 587 →Texas hospitality changed one Japanese creator's view of America during the World Cup

Keep reading

More from the desk.

78MARKETS

Three Temasek India bets each jump more than 30% after listings this week

A contrarian bet is a position placed against the prevailing market view on an asset, held until that view shifts. Singapore's state investor Temasek made those calls on three companies in India. This week, each of them jumped more than…

markets1 MIN

107MARKETS

Bridgewater trims Amazon as it adds to Shell and PG&E

Big money shifted its holdings last quarter, tilting away from technology and toward energy. Holdings, meaning the shares a fund owns at the end of a reporting period, grew for Shell and PG&E at Bridgewater Associates during the second…

markets1 MIN

116MARKETS

Pershing Square narrows its book to three names: Uber, Brookfield, and Microsoft

Concentration, in portfolio management, means putting most of a fund's capital into a small number of positions rather than spreading it across many names. Pershing Square has organized its

markets1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk